Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies
Request a Quote


High quality DMPK studies are at the heart of a successful drug discovery project. Done right, they can have a substantial impact on the development timeline, total cost of the project, and quality of the molecules that progress to the clinic.

At Sygnature we have built a DMPK team with a wealth of drug discovery experience. This enables us to do more than just deliver accurate DMPK data: we provide expert analysis and interpretation of the results. This is a key feature in helping drive your project forward.

We offer an extensive range of validated in silico, in vitro and in vivo DMPK services for drug discovery, backed up by a comprehensive portfolio of analytical techniques. We can design flexible DMPK screening cascades to support medicinal chemistry programmes, including bespoke method development.

Working closely with Chemistry and Bioscience, our approach is one of collaboration, partnering with clients to develop a greater understanding of the target and the properties that a successful drug should have. Expert guidance and problem-solving suggestions from our experienced team will help you optimise potential drug molecules, increasing the likelihood of success.

DMPK Services:

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

DMPK Services

DMPK Consultancy

Sygnature Discovery offers a range of DMPK consultancy services to drug discovery research teams within the academic, pharmaceutical, biotechnology, charity and CRO sectors as well as to life science venture capital funds.


Physicochemical Profiling

It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.


In silico and PBPK modelling

Sygnature uses the GastroPlusTM software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data integration within the context of a virtual animal or human model.


In Vitro ADME

The assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of compounds is a critical component is supporting the development of compounds within Discovery and Development. 


In Vivo Pharmacokinetics (PK)

At Sygnature Discovery we offer services to support your non-GLP in vivo Pharmacokinetics studies in preclinical species including the planning of these studies and the analysis of any samples generated by UPLC-MS



Sygnature’s state-of-the-art non-GLP bioanalysis service brings together the latest instrumentation and technology, which, combined with the wealth of experience across the team, is used to provide quantitative measures of metabolites for the purpose of pharmacokinetics, toxicokinetics, bioequivalence and exposure-response studies.


Metabolite Identification (Met-ID)

Sygnature’s DMPK and biotransformational capabilities are supplemented by extensive expertise in complementary analytical techniques, including high-resolution mass spectrometry, nuclear magnetic resonance, chemically intelligent software algorithms and mass spectrometry imaging.


Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!